Beijing, June 17 (Prensa Latina) Another inactivated Covid-19 vaccine, but obtained by a subsidiary of China’s National Pharmaceutical Group (Sinopharm), also proved effective in stimulating the immune system in clinical trials, news media reported today.
According to a statement from the company sent to the Global Times newspaper, the drug was developed by the Wuhan Institute of Biological Products, presented positive results in the first and second stage of trials and became ‘the first candidate in the world to demonstrate favorable immunogenicity and safety.
It had no significant adverse effects, was applied to 1,120 healthy individuals aged 18 to 59, and the rate of seroconversion of the neutralizing antibodies reached 100 percent.
The trials were conducted under the randomized, double-blind, placebo-controlled method.
This is the most comprehensive and effective clinical study of a Covid-19 vaccine and provides scientific data for epidemic prevention and control, and emergency use in China,’ the text said.
Sinopharm offered this and a similar substance a few days ago, but obtained by its Beijing Institute of Biological Products, to employees of the country’s state-owned companies working abroad.
Its application – requires a notification of signature – is completely voluntary, with a previously signed consent and the second dose would be administered between 14 and 28 days after the first.
On Sunday, Chinese pharmaceutical company Sinovac also announced that its inactivated CoronaVac vaccine is safe and effective against the deadly pneumonia.
Preliminary data from the studies revealed the production of antibodies in more than 90 percent of the volunteers in just 14 days and as adverse effects left mild pain at the site of application, fatigue and low fever in some of them.
Sinovac plans to soon share the results with the international community through articles and intends to proceed with the third phase of the research, which will be conducted in Brazil and will take time to complete.
However, the firm assured that it will be available for public use if CoronaVac shows positive results.
China expects that one of the six vaccines currently in clinical trials will be ready for emergency use in the autumn. Five of them were developed by domestic companies and the sixth is a project of the Chinese firm Fosun, the German BioNTech and the American Pfizer.
A few days ago the World Health Organization commented on the progress of these products, while Beijing completed the largest plant in the world to produce 100 to 120 million doses of inactivated vaccines annually.
According to the Global Times, states such as Canada, Malaysia and the United Kingdom were willing to work with China on research into these drugs, as they need to be tested abroad in view of the drop in cases of Covid-19 here.
(Taken from PL)